App-Quantinova.ai

Continuously Improving Outcome over Time after Second Allogeneic Stem Cell Transplantation in Relapsed Acute Myeloid Leukemia - a Retrospective Analysis of 1540 Patients on Behalf of the Acute Leukemia Working Party of EBMT

Ann-Kristin Schmälter - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Graft-versus-host disease

Cyclophosphamide

Higher Proportions of Monocytic-Myeloid-Derived Suppressive Cells (mMDSC) before Allotransplant Predict Relapse in Acute Leukemia Patients

Pierre Peterlin - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute Leukemia

Allopurinol

Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm Following Treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT

Mitja Nabergoj - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Alpha-thalassemia myelodysplasia syndrome

Allopurinol

Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Hani Hassoun - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers

Laurent Garderet - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Joanna Drozd-Sokolowska - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

T-cell prolymphocytic leukemia

Alemtuzumab

Autologous Stem Cell Transplant in 2nd Line DLBCL in 2022, Still the Standard of Care ? a Monocentric Experience

Aude Collignon - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Bendamustine

Long-Term Data Confirm the Superiority of Total Body Irradiation-Containing Conditioning Regimen in Comparison to a Chemotherapy-Based Preparation in Children with Acute Lymphoblastic Leukemia Above the Age of 4 Years Given an Unmanipulated Allograft. Results of the Forum Randomized Clinical Trial

Franco Locatelli - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclosporine A

Risk Factors Influencing Transplant Outcomes of Adults with Acute Lymphoblastic Leukemia in First Complete Remission: A Retrospective Analysis from the ALWP of the EBMT

Martina Calabrò - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Allopurinol

Conditioning Regimen Intensity and Donor Choice Do Not Impact Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in First Complete Remission (CR1): An EBMT Analysis

Razan Mohty - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Graft-versus-host disease

Mycophenolate mofetil

Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation for Therapy-Related Myeloid Neoplasms Following Treatment for Myeloma

Sarah Lawless - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

Allopurinol

Improved Post-Transplant Outcomes in Recent Years for AML Patients with Intermediate Karyotype, FLT3-ITD and Wild Type NPM1: A Report from the EBMT Acute Leukemia Working Party

Ali Bazarbachi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Cytomegalovirus infection

Cyclophosphamide

Impact of Allele-Level HLA-Matching on Outcomes after Double Unrelated Cord Blood Transplantation in Adults with Malignant Diseases

Giancarlo Fatobene - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study

Blanca Rius Sansalvador - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Graft-versus-host disease

N/A

Allogeneic Transplant As a Curative Option for Relapsed/Refractory Large B-Cell Lymphoma in the Era of CAR T-Cell Therapy: A Monocentric Retrospective Study

Pauline Roché - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Allopurinol

A Second Haploidentical Stem Cell Transplantation (HAPLO-SCT2) after Relapse from First Haplo-SCT Is Feasible and Produces Results That Are Comparable to Data Reported after Second SCT in an HLA-Matched Setting - a Study on Behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Giuliano Filippini Velazquez - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Graft-Versus-Leukemia Effect Is Independent from Graft-Versus-Host Disease Following Ptcy-Based HLA-Haploidentical Transplantation

Frederic Baron - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Graft-versus-host disease

Cyclophosphamide

Comparable Outcomes Following Non-First-Degree and First-Degree Related Donor Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia Patients in Complete Remission: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Yishan Ye - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Trends in the Use of Hematopoietic Stem Cell Transplantation in the Management of Relapsed/Refractory Diffuse Large B Cell Lymphoma. a Retrospective Analysis of the Lymphoma Working Party of the EBMT

Anna Sureda - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Allopurinol

Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr-Mutated Myelofibrosis

Juan Carlos Hernandez Boluda - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Graft-versus-host disease

Allopurinol

Filters

24360 Abstracts